Ágæti Umboðsmaður Alþingis

Til að læra af mistökunum og koma í veg fyrir að þau endurtaki sig er mikilvægt að Umboðsmaður Alþingis taki að eigin frumkvæði til athugunar og kanni til hlítar hvers vegna keypt voru bóluefni fyrir milljarða sem hafa þann eiginleika að þau hvorki vernda gegn sýkingu eða koma í veg fyrir smit. Bóluefni sem endurteknar rannsóknir hafa leitt í ljós að eftir því sem efninu er sprautað oftar þeim mun líklegri er bóluefnaþeginn til að taka sóttina sem bóluefnið átti að vernda fyrir. 

Hvernig gat það gerst að keypt voru bóluefni sem leitt hafa til ótímabærs dauðdaga fjölda Íslendinga en samkvæmt dánarmeinaskrá landlæknis fyrir árið 2022 fjölgaði dauðsföllum af völdum illkynja æxla um 9% á árinu. Illkynja æxli í blöðruhálskirtli dró 21% fleiri til dauða en á fyrra ári, eitilæxli 17%, mergæxli 40%, æxli í brisi 23% og dauðsföllum af völdum hvítblæðis fjölgaði um 33% frá fyrra ári. Dauðsföllum af völdum nýrnabólgu og nýrnaheilkennis fjölgaði um 29% á árinu. Dauðsföllin gefa langt í frá tæmandi mynd af umfangsmiklum skaða bóluefnanna því fjöldi landsmanna eiga við heilsubrest að etja af völdum efnanna sem m.a. birtist í mikilli fjölgun veikindadaga og leitt hefur til endurskoðunar bótafjárhæða sjúkrasjóða stéttarfélaga sem annars myndu tæmast. 

Dánarmeinaskráin gefur ekki glöggar upplýsingar um orsakir dánarmeina á árinu 2022 þar sem 213 dauðsföll, eða 8% af heildinni, voru skráð sem væru þau af völdum Covið-19. Til samanburðar voru dauðsföll samkvæmt dánarmeinaskrá af völdum Covid á árinu 2021 einungis 6. Það var einmitt af þessari ástæðu sem Þórólfi Guðnasyni fyrrverandi sóttvarnalækni var gert að taka pokann sinn í maí 2022 að hann neitaði að skrá dauðsföllin af völdum mRNA bóluefnanna sem væru þau af völdum Covid-19. 

Til hvers var unnið með 719.000 bólusetningum landsmanna við Covid á árinu 2021 ef andlátum af völdum Covid-19 fjölgar úr 6 á árinu 2021 í 213 á árinu 2022? Að ekki eitt einasta dauðsfall á árinu 2022 samkvæmt dánarmeinaskrá skuli skráð af völdum bóluefnanna kallar á skýringar og ætti að vera Umboðsmanni Alþingis sérstakt rannsóknarefni.

Örvæntingarfull tilraun til að réttlæta skaðann

Rafbyssan og áhrif á starfsemi skemmda hjartans

Mikilvægt er að bæði heilbrigðisstarfsmenn sem fá einstaklinga til meðferðar eftir að hafa verið skotnir með rafbyssu og ekki síður lögreglumenn sem taka þurfa leiftursnögga ákvörðun um beitingu vopnsins geri sér grein fyrir að töluverðar viðbótarlíkur á alvarlegum hjartaáverka kunna að fylgja notkun rafbyssunnar í kjölfar bólusetninga stórs hluta landsmanna gegn Covid-19.

Samkvæmt niðurstöðum rannsókna eru 2,8% covid mRNA bólusettra með skemmd í hjartavöðva. Flestir án þess að gera sér grein fyrir skaðanum og því ekki í stöðu til að taka upplýsta ákvörðun um hvort þeir eigi að taka áhættuna af áreynslunni á hjartavöðvann sem fylgir keppnisíþrótt sbr. atvinnumennina í knattspyrnu sem við höfum horft á hníga niður örenda á leikvellinum í beinni útsendingu síðustu misserin. Svo er það litli hópurinn með skaðaða hjartað sem hættir til að lenda upp á kant við lög og reglu og varast ekki áhrifin á hjartað sem rafstuð úr nýju vopni lögreglu kann að valda.

Morgunblaðið greinir frá bréfi ríkislögreglustjóra til heilbrigðisstarfsmanna til að upplýsa þá um hvernig eigi að meðhöndla sjúklinga sem hafa verið skotnir með rafbyssum. Í bréfinu kemur fram að miðað við tegund og styrk vopnsins megi gera ráð fyrir nokkrum flokkum áverka sem beiting þess getur haft í för með sér, beint eða óbeint. Eru dæmi nefnd eins og áhrif á rafstarfsemi hjartans.

 

Æxlunarfærin sluppu ekki

Ekki horfir gæfulega um þróun frjósemi á árinu sem er að líða því lifandi fæddum börnum á Landspítalanum fækkaði um 7,2% og fæðingum um 6,7% á fyrstu sex mánuðum ársins. Ekkert af líffærakerfunum virðist komast óskaddað frá bólusetningunum með mRNA efnunum við Covid-19 eins og starfsemi æxlunarfæra landsmanna sýnir. Stefnir því í að Hagstofan geti þriðja árið í röð notast við óbreytta fyrirsögn fréttar af frjósemi sem yrði að ári: „Frjósemi aldrei verið minni en 2024”.

Línuritið sýnir þróun fjölda kvenna á barneignaaldri og fjölda fæðinga (báðar stærðir settar á 100 2019). Að skýra fækkun fæðinga á síðustu misserum sem eðlilega í kjölfar fjölgunar barneigna eftir innilokanir er ekki lengur trúverðugt.

Tölur um fjölda látinna feimnismál

Evrópska hagfræðistofnunin hefur uppfært gagnagrunn umframdauðsfalla einstakra landa Evrópu með júní tölum. Hlutfall umframdauðsfalla á Íslandi í júní er ekki að finna í töflunni.

Samkvæmt Eurostat var hlutfall umframdauðsfalla á Íslandi 17,7% í maí s.l. þegar það var 1,7% fyrir ESB. Á vef Embættis landlæknis hefur verið að finna tölur um hlutfall umframdauðsfalla en af ókunnum ástæðum hefur taflan ekki verið uppfærð frá 10.6. s.l. en til þess tíma var hún uppfærð mánaðarlega og síðast með apríl hlutfallinu.

Tímabil grafarþagnar um fjölda látinna Íslendinga er hafið. Landsmenn komast næst því að geta sér til um fjölda dauðsfalla með talningu dánartilkynninga í blaði allra landsmanna.

Súlurritið sýnir hlutfall umframdauðsfalla á Íslandi (rauðar súlur) og ESB (bláar súlur) síðustu 11 mánuði samkvæmt vef Evrópsku hagstofunnar. Tafir á upplýsingum um fjölda látinna Íslendinga endurspeglar vandræðaganginn við framleiðslu dánartalna þar sem Íslendingum sem mæta ótímabærum dauðdaga fyrir tilverknað mRNA bóluefnanna fækkar ekki þrátt fyrir að mjög hafi dregið úr áhuga eldri borgara á bólusetningum.

Kári tekur undir kröfu um rannsókn

Hætta á hjartavöðvabólgu margfaldaðist eftir mRNA covid bólusetningu

Niðurstöður óvenju umfangsmikillar ritrýndrar rannsóknar í Suður Kóreu leiddu í ljós 620% aukna hættu á hjartavöðvabólgu meðal mRNA covid bólusettra og 175% aukna hættu á gollurhússbólgu samanborið við söguleg viðmið. Heilsufarsupplýsingar 99% þjóðarinnar lágu undir í rannsókninni hverra niðurstöður voru birtar nýlega í Nature Communications. Fylgst var með 4.5 milljónum bólusettra einstaklinga að meðaltali í 15 mánuði eftir bólusetningu. Þar sem hátt bólusetningarhlutfall fullorðinna í Suður Kóreu (96,6%) kom í veg fyrir samanburð við nægilega stórt úrtak óbólusettra voru söguleg gögn fyrir upphaf bólusetninga þ.e.  til 31.12.20 notuð fyrir viðmiðunarhópinn og fylgst með bólusetta hópnum til 31.12.22.

Vísindagreinar um skaðsemi covid bóluefnanna

Ljóst er af neðangreindri upptalningu vísindagreina, sem margar eru ritrýndar, ásamt greinum sem birst hafa í fagtímaritum um skaðsemi covid bóluefnanna að þúsundir vísindamanna taka ekki undir fullyrðingar um að bóluefnin til varnar Covid-19 flensunni séu bæði örugg og gagnleg sem sýkinga- og smitvörn og hafa rökstutt það viðhorf með niðurstöðum rannsókna. Áhugasamir geta hér nálgast hlekki á greinarnar ásamt stuttri lýsingu á efni þeirra. Greinarnar eru gróflega flokkaðar eftir skaða af völdum bóluefnanna eftir sjúkdómum eða skaða á einstök líffæri eða líffærakerfi. Hér er einungis listi yfir á annað hundruð rannsóknir en þær skipta orðið þúsundum.

General Adverse Events

1. Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials
2. Potential health risks of mRNA-based vaccine therapy: A hypothesis
3. ‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA
4. The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review
5. COVID-19 vaccines – An Australian Review
6. National Academies Committee on Review of Relevant Literature Regarding Adverse Events Associated with Vaccines March 30 2023: Written material accompanying oral remarks
7. Is the US’s Vaccine Adverse Event Reporting System broken?
8. Gene-based COVID-19 vaccines: Australian perspectives in a corporate and global context
9. mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review
10. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals
11. Exploring COVID-19 Vaccines ‘Safety Signal’ Data on Vigiaccess.org: A World Council for Health Report
12. The mRNA-LNP vaccines – the good, the bad and the ugly?
13. N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting
14. Broad-spectrum of non-serious adverse events following COVID-19 vaccination: A population-based cohort study in Seoul, South Korea
15. Hematologic abnormalities after COVID-19 vaccination: A large Korean population-based cohort study
16. BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists
17. Concern about the Effectiveness of mRNA Vaccination Technology and Its Long-Term Safety: Potential Interference on miRNA Machinery
18. Potential health risks of mRNA-based vaccine therapy: A hypothesis
19. Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms
20. SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination
21. The spike hypothesis in vaccine-induced adverse effects: questions and answers
22. Curing the pandemic of misinformation on COVID-19 mRNA vaccines through real evidence-based medicine - Part 1
23. Shedding of infectious SARS-CoV-2 despite vaccination
24. COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities
25. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs
26. The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice
27. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
28. Previous COVID-19 infection but not Long-COVID is associated with increased adverse events following BNT162b2/Pfizer vaccination
29. On COVID vaccines: why they cannot work, and irrefutable evidence of their causative role in deaths after vaccination
30. Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?
31. Inability to work following COVID-19 vaccination–a relevant aspect for future booster vaccinations
32. The anti-SARS-CoV-2 BNT162b2 vaccine suppresses mithramycin-induced erythroid differentiation and expression of embryo-fetal globin genes in human erythroleukemia K562 cells
33. US COVID-19 Vaccines Proven to Cause More Harm than Good Based on Pivotal Clinical Trial Data Analyzed Using the Proper Scientific Endpoint, “All Cause Severe Morbidity”
34. Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19
35. Long-term adverse events of three COVID-19 vaccines as reported by vaccinated physicians and dentists, a study from Jordan and Saudi Arabia

Autoimmune

1. Oncogenesis and autoimmunity as a result of mRNA COVID-19 vaccination
2. The Potential Role of SARS-CoV-2 Infection and Vaccines in Multiple Sclerosis Onset and Reactivation: A Case Series and Literature Review
3. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
4. Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues
5. Role of the antigen presentation process in the immunization mechanism of the genetic vaccines against COVID-19 and the need for biodistribution evaluations
6. New-onset autoimmune phenomena post-COVID-19 vaccination
7. IgA Vasculitis Following COVID-19 Vaccination: A French Multicenter Case Series Including 12 Patients
8. Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues
9. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine
10. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink
11. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity
12. Pathogenic antibodies induced by spike proteins of COVID-19 and SARS-CoV viruses

Blood Clots & Fibrous Clots

1. COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes
2. Extensive splanchnic vein thrombosis after SARS-CoV-2 vaccination: A Vascular Liver Disease Group (VALDIG) initiative
3. Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19
4. Safety Profiles of mRNA COVID-19 Vaccines Using World Health Organization Global Scale Database (VigiBase): A Latent Class Analysis
5. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia
6. Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series
7. Thromboembolic Events after COVID-19 Vaccination: An Italian Retrospective Real-World Safety Study
8. Incidence and outcomes of splanchnic vein thrombosis after diagnosis of COVID-19 or COVID-19 vaccination: a systematic review and meta-analysis
9. Factors associated with stroke after COVID-19 vaccination: a statewide analysis

Cancer

1. SARS-CoV-2 Vaccination and the Multi-Hit Hypothesis of Oncogenesis
2. Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure
3. Oncogenesis and autoimmunity as a result of mRNA COVID-19 vaccination
4. Types and Rates of COVID-19 Vaccination in Patients With Newly Diagnosed Microsatellite Stable and Instable Non-Metastatic Colon Cancer
5. Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
6. SARS-CoV-2 spike S2 subunit inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells
7. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
8. S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: an in silico study
9. The CD147 Epitope on SARS CoV2 and the Spike in Cancer, Autoimmunity and Organ Fibrosis
10. Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan

Cardiac

1. Determinants of COVID-19 vaccine-induced myocarditis
2. OpenSAFELY: Effectiveness of COVID-19 vaccination in children and adolescents
3. Improved diagnosis of COVID-19 vaccine-associated myocarditis with cardiac scarring identified by cardiac magnetic resonance imaging
4. Forensic analysis of the 38 subject deaths in the 6-Month Interim Report of the Pfizer/BioNTech BNT162b2 mRNA Vaccine Clinical Trial
5. Cardiac side effects of RNA-based SARS-CoV-2 vaccines: Hidden cardiotoxic effects of mRNA-1273 and BNT162b2 on ventricular myocyte function and structure
6. Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients
7. Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2–vaccinated and Nonvaccinated Patients
8. Cardiovascular Assessment up to One Year After COVID-19 Vaccine–Associated Myocarditis
9. Sex-specific differences in myocardial injury incidence after COVID-19 mRNA-1273 booster vaccination
10. Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis
11. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis
12. Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study
13. Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic
14. Catecholamines Are the Key Trigger of COVID-19 mRNA Vaccine-Induced Myocarditis: A Compelling Hypothesis Supported by Epidemiological, Anatomopathological, Molecular, and Physiological Findings
15. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study
16. Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?
17. SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
18. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021
19. Changes of ECG [EKG] parameters after BNT162b2 vaccine in the senior high school students
20. Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults
21. Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis
22. Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination
23. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection
24. BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis
25. Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study
26. Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave
27. Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
28. Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines
29. Risk of Myopericarditis following COVID-19 mRNA vaccination in a Large Integrated Health System: A Comparison of Completeness and Timeliness of Two Methods
30. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex
31. SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis
32. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination
33. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents
34. Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong
35. Myocarditis and Pericarditis After Vaccination for COVID-19
36. Abstract 10712: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines
37. The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients-A Large Population-Based Study
38. COVID-19-Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review
39. Adjuvants in COVID-19 vaccines: innocent bystanders or culpable abettors for stirring up COVID-heart syndrome
40. Arrhythmias after COVID-19 Vaccination: Have We Left All Stones Unturned?
41. Risks of Cardiac Arrhythmia Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Dermatological

1. New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review
2. Management of oral lesions following COVID-19 vaccination
3. Occurrence of erythema multiforme following COVID-19 vaccination: a review
4. Incidence of Chronic Spontaneous Urticaria Following Receipt of the COVID-19 Vaccine Booster in Switzerland
5. A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders
6. Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination

Diabetes

1. Metformin mitigates insulin signaling variations induced by COVID-19 vaccine boosters in type 2 diabetes
2. Hyperglycemic Emergencies Associated With COVID-19 Vaccination: A Case Series and Discussion

Eye Disorders

1. Characteristics and Clinical Ocular Manifestations in Patients with Acute Corneal Graft Rejection after Receiving the COVID-19 Vaccine: A Systematic Review
2. Risk assessment of retinal vascular occlusion after COVID-19 vaccination
3. COVID-19 Vaccine-Associated Optic Neuropathy: A Systematic Review of 45 Patients
4. The Eye of the Storm: COVID-19 Vaccination and the Eye
5. Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective
6. UVEITIS AFTER THE BNT162b2 mRNA VACCINATION AGAINST SARS-CoV-2 INFECTION: A Possible Association
7. Retinal Toxicity of Polyethylene Glycol (PEG)-400

Increased Susceptibility to C19 Infection

1. Risk of SARS-CoV-2 infection and hospitalization in individuals with natural, vaccine-induced and hybrid immunity: a retrospective population-based cohort study from Estonia
2. IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein
3. Forgotten “Primum Non Nocere” and Increased Mortality after COVID-19 Vaccination
4. Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine (Known as the Cleveland Clinic study
5. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
6. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
7. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
8. Conserved longitudinal alterations of anti-S-protein IgG subclasses in disease progression in initial ancestral Wuhan and vaccine breakthrough Delta infections
9. Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection
10. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
11. Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States
12. Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease
13. Effects of Vaccination and Previous Infection on Omicron Infections in Children
14. (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study
15. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
16. Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals

Inflammation

1. Correlation between COVID-19 vaccination and inflammatory musculoskeletal disorders
2. New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review
3. Abstract 10712: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines
4. Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigatio
5. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis
6. Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination
7. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

Kidney / Renal Issues

1. Renal Complications Following COVID-19 Vaccination: A Narrative Literature Review
2. Daily Clout Report 62: Acute Kidney Injury and Acute Renal Failure Following Pfizer mRNA COVID Vaccination
3. Case Report: Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Renal Failure and Pulmonary Hemorrhage May Occur After COVID-19 Vaccination
4. Successful treatment of new-onset diabetes mellitus and IgA nephropathy after COVID-19 vaccination: a case report
5. Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine

Long COVID versus Long Vax

1. Long COVID: Sufferers can take heart
2. Persistence of S1 Spike Protein in CD16+ Monocytes up to 245 Days in SARS-CoV-2 Negative Post COVID-19 Vaccination Individuals with Post-Acute Sequalae of COVID-19 (PASC)-Like Symptoms
3. Presence of viral spike protein and vaccinal spike protein in the blood serum of patients with long-COVID syndrome
4. Characteristics and predictors of Long COVID among diagnosed cases of COVID-19
5. The prevalence of post-COVID-19 vaccination syndrome and quality of life among COVID-19-vaccinated individuals
6. Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization
7. Association between virus variants, vaccination, previous infections, and post-COVID-19 [“Long Covid”] risk
8. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae
9. Strategies for the Management of Spike Protein-Related Pathology
10. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19
11. Long-COVID Prevalence and Its Association with Health Outcomes in the Post-Vaccine and Antiviral-Availability Era

Neurological Issues

1. Prenatal Exposure to COVID-19 mRNA Vaccine BNT162b2 Induces Autism-Like Behaviors in Male Neonatal Rats
2. Emergence of a New Creutzfeldt-Jakob Disease: 26 Cases of the Human Version of Mad-Cow Disease, Days After a COVID-19 Injection
3. COVID-19 vaccination-related tinnitus is associated with pre-vaccination metabolic disorders
4. Audiovestibular adverse events following COVID-19 vaccinations
5. Vestibular Neuritis Following COVID-19 Vaccination: A Retrospective Study
6. Vertigo/dizziness following COVID-19 vaccination
7. Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms
8. NEURO-COVAX: An Italian Population-Based Study of Neurological Complications after COVID-19 Vaccinations
9. Neurological Adverse Reactions to SARS-CoV-2 Vaccines
10. SARS-CoV-2 Spike amyloid fibrils specifically and selectively accelerates amyloid fibril formation of human prion protein and the amyloid β peptide
11. Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection
12. SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges- Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19
13. CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
14. A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review
15. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States
16. Neurological Complications Following COVID‐19 Vaccination
17. Sudden Hearing Loss Following Vaccination Against COVID-19
18. Development of facial palsy following COVID-19 vaccination: A systematic review
19. COVID-19 RNA Based Vaccines and the Risk of Prion Disease
20. SARS-CoV-2 S1 Protein Induces Endolysosome Dysfunction and Neuritic Dystrophy
21. Neurological consequences of COVID-19 and brain related pathogenic mechanisms: A new challenge for neuroscience
22. Immediate and 6-month seizure outcomes following first and second SARS-CoV2 mRNA vaccinations: A multicenter study with a nationwide survey
23. Factors associated with stroke after COVID-19 vaccination: a statewide analysis

Reactivation of Latent Viruses

1. Association of herpes zoster with COVID-19 vaccination: A systematic review and meta-analysis

Reproductive Issues

1. Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination
2. Increased risk of fetal loss after COVID-19 vaccination
3. Abnormal Uterine Bleeding Among COVID-19 Vaccinated and Recovered Women: a National Survey
4. A Nationwide Survey of mRNA COVID-19 Vaccinee’s Experiences on Adverse Events and Its Associated Factors
5. Evaluation of menstrual symptoms after Coronavirus disease 2019 vaccination in women with endometriosis
6. Female reproduction and abnormal uterine bleeding after COVID-19 vaccination
7. Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination
8. Prevalence of and risk factors for self-reported menstrual changes following COVID-19 vaccination: a Danish cohort study
9. Association between Different Types of COVID-19 Vaccines and Menstrual Cycle Patterns among Women of Reproductive Age
10. Unexpected vaginal bleeding and COVID-19 vaccination in non-menstruating women
11. Biodistribution of mRNA COVID-19 vaccines in human breast milk
12. Premenstrual and menstrual changes reported after COVID-19 vaccination: The EVA project
13. Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy
14. Analysis of Vaccine Reactions After COVID-19 Vaccine Booster Doses Among Pregnant and Lactating Individuals
15. COVID-19 Vaccines: The Impact on Pregnancy Outcomes and Menstrual Function
16. Japanese Pfizer biodistribution studies translated: SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048) 2.6.4 Summary statement of the pharmacokinetic study
17. Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk
18. Menstrual cycle disturbances after COVID-19 vaccination
19. The effect of BNT162b2 SARS-CoV-2 mRNA vaccine on menstrual cycle symptoms in healthy women
20. Covid-19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors
21. Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women

Reverse Transcription of the Genome

1. Methodological Considerations Regarding the Quantification of DNA Impurities in the COVID-19 mRNA Vaccine Comirnaty®
2. Presence of viral spike protein and vaccinal spike protein in the blood serum of patients with long-COVID syndrome
3. DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events
4. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose
5. SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome
6. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line
7. mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues

Thyroid Dysfunction

1. Effect of SARS-CoV-2 BNT162b2 mRNA vaccine on thyroid autoimmunity: A twelve-month follow-up study

Vaccine Shedding

1. Inadvertent Exposure to Pharmacologically Designed Lipid Nanoparticles Via Bodily Fluids: Biologic Plausibility and Potential Consequences
2. SHEDDING OF COVID mRNA VACCINES: A review of the available evidence
3. Current state of knowledge on the excretion of mRNA and spike produced by anti-COVID-19 mRNA vaccines; possibility of contamination of the entourage of those vaccinated by these products

Excess Deaths & SADS

1. Spatiotemporal variation of excess all-cause mortality in the world (125 countries) during the Covid period 2020-2023 regarding socio economic factors and public-health and medical interventions
2. COVID-19 Illness and Vaccination Experiences in Social Circles Affect COVID-19 Vaccination Decisions
3. COVID-19 vaccine-associated mortality in the Southern Hemisphere
4. A Systematic REVIEW of Autopsy findings in deaths after covid-19 vaccination
5. Is There a Link between the 2021 COVID-19 Vaccination Uptake in Europe and 2022 Excess All-Cause Mortality?
6. Deaths by vaccination status, England
7. Excess mortality in Germany 2020-2022
8. Postmortem investigation of fatalities following vaccination with COVID-19 vaccines
9. Anti-SARS-CoV-2 Immune Response and Sudden Death: Titin as a Link
10. Risk of COVID Vaccine-Induced Fatality is Equal to or Greater than the Risk of a COVID death for all Age Groups Under 80 Years Old
11. Covid-19: Pfizer-BioNTech vaccine is “likely” responsible for deaths of some elderly patients, Norwegian review finds
12. US - Trends in Death Rates from Neoplasms, Ages 15-44

Other Articles Compiling Studies on Vaccine Injury

Af hverju hætti Þórólfur?

Meðalævin styttist tvö ár í röð

Ólifuð meðalævi karla við fæðingu hefur styst um 0,7 ár og kvenna um 0,6 ár frá 2021. Meðalævi landsmanna hefur með örfáum undatekningum lengst á hverju ári síðustu áratugi en eftir styttingu síðustu tveggja ára er meðalævin nú orðin svipuð og hún var fyrir 10 til 12 árum. 

Lokaorð eftirminnilegs svars Guðrúnar Aspelund sóttvarnalæknis, þar sem læknirinn var spurður álits á niðurstöðum ítalskrar rannsóknar í milljóna héraði á Ítalíu sem sýndu augljósa fylgni milli mRNA bólusetninganna gegn covid og fjölgunar dauðsfalla sem fylgdu, voru þau að „það er algjörlega búið að sýna fram á það að Covid-19 bóluefnin eru gagnleg og ávinningur langt umfram áhættu.“ Að þeim stóradómi föllnum er ekki nema von að menn spyrji hvernig á því standi að meðalævi Íslendinga hafi tekið að styttast fyrir tveimur árum eftir að landsmenn höfðu þegið yfir 700.000 bóluefnaskammta  gegn covid með „namminu“ hans Kára Stefánssonar? Hvernig standi á því að dánartíðni ungbarna hækki um 64% á árinu 2023 hvort sem miðað er við fyrra ár eða meðaltal áranna 2018/2019?